<DOC>
	<DOCNO>NCT00335712</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety pharmacokinetics ONO-5129 patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Pilot Study ONO-5129 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Fasting Blood Glucose 126250mg/dL 2 . HbA1c 6.511 % 1 . Previous treatment antidiabetic agent equal less 23 month prior randomization 2 . History myocardial infarction , coronary artery surgery 3 . Other eligibility criterion specify study protocol</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-5129</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>